Lineage Cell Therapeutics, Inc. Contract Liability (Deferred Revenue)
Lineage Cell Therapeutics, Inc. (LCTX) had Contract Liability (Deferred Revenue) of $10.10 million as of 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-05-09
- 2024-03-31: Contract with Customer, Liability, Current $10.10M.
- 2023-12-31: Contract with Customer, Liability, Current $10.80M.
- 2023-09-30: Contract with Customer, Liability, Current $9.91M.
- 2023-06-30: Contract with Customer, Liability, Current $33.70M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2024-03-31 | $10.10M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $10.80M 10-Q · filed 2024-05-09 | |
| 2023-09-30 | $9.91M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $33.70M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $36.60M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $9.40M 10-K · filed 2024-03-07 | $38.70M 10-K · filed 2023-03-09 |
| 2022-09-30 | $40.50M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $43.10M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $47.30M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $52.10M 10-K · filed 2022-03-10 | |
| 2021-09-30 | $3.00M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $613.00K 10-Q · filed 2021-08-12 | |
| 2020-12-31 | $193.00K 10-Q · filed 2021-08-12 | |
| 2020-09-30 | $46.00K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $297.00K 10-Q · filed 2020-08-06 | |
| 2019-12-31 | $45.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $44.00K 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $43.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $42.00K 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $309.00K 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |